Globally, 58 million people are living with hepatitis C virus (HCV) infection and 1.5 million new patients are infected every year. The advent of direct-acting antivirals (DAAs) has revolutionized the treatment of HCV, opening the door to the ambitious World Health Organization HCV infection elimination strategy by 2030. However, emerging resistance to DAAs could jeopardize any hope of achieving these targets.
A case report, published in Oxford Medical Case Reports, discussed a series of 18 patients within a resource-limited setting, who after failing standard sofosbuvir/daclatasvir-based regimen also failed to respond to advanced pan-genotypic treatment regimens, i.e. sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/ribavirin and sofosbuvir/velpatasvir/voxilaprevir. To avoid the spread of refractory HCV strains within the existing epidemic, the report called for increased attention and research regarding patients failing treatment on standard pan-genotypic regimens and the spread of HCV-resistant strains within the communities.
The full case report can be accessed here.